2016_Head & Neck COURSE BOOK

Conclusions and take home mesage

Cetuximab does not seem to increase the risk of RT mucositis but acute grade 4 dermatitis has been described.

Systemic cutaneous toxicity of anti-Epidermal Growth Factor Receptor i hibit b t t d d di th t ith n ors can e rea e epen ng on e symp oms w - antiacne or antirosacea cream (erythromycin or clindamycin gel)

- topical corticosteroids, - antihistaminic if itching, - oral tetracycline (minocycline 100 mg/day)

Around 60% of the patients will develop long term xerostomia. The incidence of xerostomia could be reduced by IMRT.